Health and Healthcare

Short Interest in Major Pharma Takes a Giant Leap

Thinkstock

The short interest data have been released for the November 30 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug is approved or passes a clinical trial, there can be big upside.

The November 30 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was up.

Pfizer Inc. (NYSE: PFE) saw its short interest jump to 65.52 million shares from the previous 49.41 million. In February, short interest spiked incredibly, and since that time it has slowly backed off. The highest short interest reading on the year was 207.4 million. Shares of Pfizer closed Wednesday at $32.29, within a 52-week trading range of $28.47 to $36.46.

Merck & Co. Inc. (NYSE: MRK) saw short interest increase to 24.81 million shares from 23.78 million in the previous period. Merck shares closed Wednesday at $52.82, in a 52-week trading range of $45.69 to $63.62.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) short interest rose to 7.19 million shares. The previous level was 4.80 million. The highest level in the past 52 weeks was 10.25 million in mid-August. Shares of Teva closed Wednesday at $65.46, in a 52-week range of $54.17 to $72.31.

Bristol-Myers Squibb Co. (NYSE: BMY) saw its short interest increase to 23.30 million shares from the previous reading of 20.83 million. Bristol-Myers shares closed Wednesday at $68.56, within a 52-week range of $51.82 to $70.54.

AbbVie Inc. (NYSE: ABBV) short interest increased to 20.23 million shares from the previous level of 17.52 million. Short interest has backed way off its highest level year to date in May. Shares of AbbVie closed Wednesday at $56.03, in a 52-week trading range of $45.45 to $71.60.

Are You Ahead, or Behind on Retirement?

If you’re one of the over 4 Million Americans set to retire this year, you may want to pay attention. Many people have worked their whole lives preparing to retire without ever knowing the answer to the most important question: am I ahead, or behind on my goals?

Don’t make the same mistake. It’s an easy question to answer. A quick conversation with a financial advisor can help you unpack your savings, spending, and goals for your money. With Zoe Financial’s free matching tool, you can connect with trusted financial advisors in minutes. 

Why wait? Click here to get started today!

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.

AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.